InsiderDB
Sign inStart free trial

Regeneron Pharmaceuticals (REGN)

Healthcare · Biotechnology

14 members of Congress have disclosed 48 trades in Regeneron Pharmaceuticals (REGN) since 2014: 21 buys and 27 sales. The most recent was disclosed on Nov 5, 2026. 1 trade was made by members of a committee that oversees Regeneron Pharmaceuticals's industry.

Trades disclosed
48
Members trading
14
Buys / sells
21 / 27
Reported value
$104K–$860K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow REGN

What else is happening at REGN

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. REGNLobbying report·Lobbying disclosures

    REGN: third_quarter 2026 lobbying report

    Biodefense funding

    Public: Nov 3, 2026, 12:49 PM ESTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. REGNFinancial report·SEC EDGAR

    REGN: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 30, 2026, 6:55 AM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. REGNCompany announcement·SEC EDGAR

    REGN: Financial results

    Filed 8-K for an event or period dated 2026-10-30. Financial results.

    Public: Oct 30, 2026, 6:50 AM EDTEvent / period: Oct 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  4. REGNLobbying report·Lobbying disclosures

    REGN: third_quarter 2026 lobbying report

    Intellectual property legislation related to biopharmaceutical manufacturers. Trade and tariff issues related to corporations; outbound investment restrictions related to biopharmaceutical manufacturers. Tax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration and manufacturing issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Biosimilar issues related to biopharmaceuti

    Public: Oct 20, 2026, 8:39 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  5. REGNLobbying report·Lobbying disclosures

    REGN: third_quarter 2026 lobbying report

    Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers

    Public: Oct 20, 2026, 12:40 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

Committee overlaps

Trades by members of a committee that oversees Regeneron Pharmaceuticals's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded REGN

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.